Cited by 2,575Multiple Myeloma Research and TreatmentsBone health and treatmentsChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Open access

Singhal, Seema, Mehta, Jayesh, Desikan, Raman, Ayers, Dan, Roberson, Paula, Eddlemon, Paul, Munshi, Nikhil, Anaissie, Elias, Wilson, Carla, Dhodapkar, Madhav, Zeldis, Jerome, Siegel, David, Crowley, John, Barlogie, Bart·1999·New England Journal of Medicine

DOI 10.1056/nejm199911183412102

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. METHODS: Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. RESULTS: The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of event-free survival and overall survival for all patients were 22+/-5 percent and 58+/-5 percent, respectively. CONCLUSIONS: Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.

Integrity signals

Registry

Crossref · 10.1056/nejm199911183412102

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Bone marrow transplant
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,373
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Unbalanced repeated-measures models with structured covariance matrices.
Jennrich, R., & Schluchter, M. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,382
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191

Show all 35 references

Research works printed but not linked: 10

Barlogie B, 1997, Clin Cancer Res, 3, 2605
Singhal S, 1996, Blood, 88, 611a
Munshi N, 1998, Blood, 92, 98a
10.2307/2281868 · DOI · Paper page
Mantel N, 1966, Cancer Chemother Rep, 50, 163
Figg WD, 1997, Proc Am Soc Clin Oncol, 16, 333a
Fine HA, 1997, Proc Am Soc Clin Oncol, 16, 385a
Long G, 1998, Proc Am Soc Clin Oncol, 17, 181a
Eisen T, 1998, Proc Am Soc Clin Oncol, 17, 441a
Nguyen M, 1997, Int J Oncol, 10, 965

Sorted by citations

Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,518
Clinical translation of angiogenesis inhibitors
Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,538
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 985
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citation
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, P., Avet‐Loiseau, H., Lonial, S., Usmani, S. Z., Siegel, D. S. D., Anderson, K. C., Chng, W. J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 949
Self-citation
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Davies, F. E., Raje, N. S., Hideshima, T., Lentzsch, S., Young, G. Q., Tai, Y., Lin, B. K., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 912
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P. G. G., Mitsiades, C. S., Mitsiades, N., Hayashi, T., Munshi, N. C., Dang, L., Castro, A. C., Palombella, V. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 899
Self-citation
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 864
Multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 884
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K. S., & Dalgleish, A. G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1323 · Cited by 817
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 802
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citation
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 821
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
Hlatky, L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.12.883 · Cited by 786
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J. R., Siegel, D. S. D., Irwin, D. H., Richardson, P. G. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 726
Self-citation
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G. J. K., Anaissie, E. J., Shaughnessy, J. D., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K. A., Pineda‐Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 731
Self-citation
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
Multiple myeloma
Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 708
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citation
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 680
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub‐Agha, I., Bourhis, J.-H., Garderet, L., Pegourié, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 663
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Richardson, P. G. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J. R., Singhal, S., Siegel, D. S. D., Irwin, D. H., Schuster, M. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 644
Self-citation
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Thalidomide
FRANKS, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 616
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K. B., & Alexanian, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 565
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.-T., Lin, B. K., Lentzsch, S., Davies, F. E., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 555
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 552
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
Matsui, W. H., Wang, Q., Barber, J. P., Brennan, S. K., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3096 · Cited by 539
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Barlogie, B., Desikan, R. K., Eddlemon, P., Spencer, T., Zeldis, J. B., Munshi, N. C., Badros, A. Z., Zangari, M., Anaissie, E. J., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 539
Self-citation
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Recent major improvement in long-term survival of younger patients with multiple myeloma
Brenner, H., Gondos, Á., & Pulte, D. D. (2007) · Blood · doi:10.1182/blood-2007-08-104984 · Cited by 533
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T. A., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 541
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citation
Tumor necrosis factor or tumor promoting factor?
Balkwill, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00020-x · Cited by 520
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Pathogenesis and Pathophysiology of Pneumococcal Meningitis
Mook-Kanamori, B. B., Geldhoff, M., van der Poll, T., & van de Beek, D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-11 · Cited by 492
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
Zangari, M., Anaissie, E. J., Barlogie, B., Badros, A. Z., Desikan, R. K., Gopal, A. V., Morris, C., Toor, A. A., Siegel, E. R., Fink, L. M., et al. (2001) · Blood · doi:10.1182/blood.v98.5.1614 · Cited by 490
Self-citation
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Varettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 489
Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party
Augustson, B. M., Begum, G., Dunn, J., Barth, N. J., Davies, F. E., Morgan, G. J., Behrens, J., Smith, A. G., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., D, D. C. G., Ashburner, B. P., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 477
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 481
Self-citation
Treatment of multiple myeloma
Barlogie, B., Shaughnessy, J. D., Tricot, G. J. K., Jacobson, J. L., Zangari, M., Anaissie, E. J., Walker, R., & Crowley, J. J. (2003) · Blood · doi:10.1182/blood-2003-04-1045 · Cited by 466
Self-citation
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El‐Rayes, B. F., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 479
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 465
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
Hwang, T. J., Carpenter, D. P., Lauffenburger, J. C., Wang, B., Franklin, J. M., & Kesselheim, A. S. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.6008 · Cited by 466
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
Durie, B. G. M., Kyle, R. A., Belch, A. R., Bensinger, W., Bladé, J., Boccadoro, M., Child, J. A., Comenzo, R. L., Djulbegović, B., Fantl, D. B. E., et al. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200312 · Cited by 425
Self-citation
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc952 · Cited by 417
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D. J., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T. B., Nordgren, B. K., Detweiler‐Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 426
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
Podar, K., Tai, Y., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D. K., Shima, Y., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.2.428 · Cited by 412
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220965528 · Cited by 402
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications
Hideshima, T., Chauhan, D., Schlossman, R. L., Richardson, P. G. G., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 393
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A. G., & Alexanian, R. (2000) · Blood · doi:10.1182/blood.v96.6.2037 · Cited by 393
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Hulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 379
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.
Winter, P. M., Caruthers, S. D., Kassner, A., Harris, T. D., Chinen, L. K., Allen, J. S., Lacy, E. K., Zhang, H., Robertson, J. D., Wickline, S. A., et al. (2003) · PubMed · Cited by 375
Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006
Cronin-Fenton, D. P., Søndergaard, F. L., Pedersen, L. H., Fryzek, J. P., Cetin, K., Acquavella, J., Baron, J. A., & Sørensen, H. T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605883 · Cited by 373
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C. L., Trudel, S., Hentz, J. G., Noble, B. N., Pirooz, N. A., Spong, J., Píza, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 377
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yüzügülen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 401
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., Vivo, A. D., Testoni, N., Nicci, C., Terragna, C., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0522 · Cited by 370
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J. L. C., Schenone, M., Prunotto, M., & Mercola, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 388
Chemotherapy-induced thrombosis
Haddad, T. C., & Greeno, E. W. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2005.10.015 · Cited by 359
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A. P., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 357
Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma
Bross, P. F., Kane, R. C., Farrell, A. T., Abraham, S., Benson, K. A., Brower, M. E., Bradley, S. P., Gobburu, J. V. S., Goheer, A., Lee, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0781 · Cited by 344
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Immunodeficiency and immunotherapy in multiple myeloma
Pratt, G., Goodyear, O. C., & Moss, P. A. H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06705.x · Cited by 342
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Self-citation
Cancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 355
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2008) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 341
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Barlogie, B., Anaissie, E. J., van Rhee, F., Haessler, J., Hollmig, K. A., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y. M., Tricot, G. J. K., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 330
Self-citation
Multiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach
Jung, H. S., Han, J., Shi, H., Koo, S., Singh, H., Kim, H.-J., Sessler, J. L., Lee, J. Y., Kim, J., & Kim, J. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02396 · Cited by 326
Endogenous angiogenesis inhibitors
Folkman, J. (2004) · Apmis · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0100 · Cited by 322
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
Desikan, R. K., Barlogie, B., Sawyer, J. R., Ayers, D., Tricot, G. J. K., Badros, A. Z., Zangari, M., Munshi, N. C., Anaissie, E. J., Spoon, D., et al. (2000) · Blood · doi:10.1182/blood.v95.12.4008 · Cited by 319
Self-citation
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
Oakervee, H. E., Popat, R., Curry, N. S., Smith, P., Morris, C., Drake, M. B., Agrawal, S. G., Stec, J., Schenkein, D. P., Esseltine, D.-L. W., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05519.x · Cited by 318

Authors: Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Siegel, D., Crowley, J., & Barlogie, B.
Affiliations: University of South Carolina (US)
University of Arkansas for Medical Sciences (US)
Rockefeller University (US)
ORCID: Singhal, Seema
Desikan, Raman
Roberson, Paula
Munshi, Nikhil
Dhodapkar, Madhav
Zeldis, Jerome
Siegel, David
Barlogie, Bart
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1999-11-18
Volume: 341
Issue: 21
Pages: 1565-1571
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199911183412102
OpenAlex: W2316160054
Cited by: 2,575
References: 35
Citations by year: 2026: 27 · 2025: 41 · 2024: 48 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 62 · 2019: 67 · 2018: 56 · 2017: 62 · 2016: 69 · 2015: 75 · 2014: 76 · 2013: 102 · 2012: 89
FWCI: 69.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01CA055819, CA-55819)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords: thalidomide, multiple myeloma, refractory multiple myeloma, anti-angiogenic therapy, Bence Jones protein, microvessel density, event-free survival, overall survival, adverse effects
MeSH terms: Bence Jones Protein, Bone Marrow, Bone Marrow Examination, Drug Administration Schedule, Female, Humans, Male, Microcirculation, Middle Aged, Multiple Myeloma, Myeloma Proteins, Recurrence, Remission Induction, Thalidomide, Multivariate Analysis, Survival Analysis, Disease Progression, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks